Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-04-04

FDA Approved: VALSARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Aurobindo Pharma Limited)

View source ↗

Summary

FDA approved a supplemental application for a generic fixed-dose combination of valsartan and hydrochlorothiazide by Aurobindo Pharma Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Valsartan and Hydrochlorothiazide (Valsartan and Hydrochlorothiazide)

Snippet

SUPPL AP for VALSARTAN AND HYDROCHLOROTHIAZIDE (VALSARTAN AND HYDROCHLOROTHIAZIDE)